8-K: Organogenesis ReNu Phase 3 Misses Primary Endpoint

Organogenesis Holdings Inc. announced its second Phase 3 trial for ReNu, a knee osteoarthritis treatment, did not achieve statistical significance for its primary pain reduction endpoint, despite numerical improvement.

Summary

• The second Phase 3 randomized controlled trial (RCT) of ReNu, a cryopreserved amniotic suspension allograft (ASA) for knee osteoarthritis (OA), did not achieve statistical significance for its primary endpoint.
• The primary endpoint was the difference between ReNu and Saline groups in the reduction in knee pain at six months, assessed by the Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain scale.
• The study demonstrated a numerical improvement of -0.5 favoring ReNu (p=0.0393 one-sided p-value), which was above the target threshold of p=0.023 for statistical significance.
• Baseline pain reduction at six months for ReNu was -6.9 in the second Phase 3 study, compared to -6.0 in the first Phase 3 study.
• The first Phase 3 trial achieved a statistically significant improvement of -0.7 favoring ReNu (p=0.0177, one-sided p-value) against the same p=0.023 target threshold.
• ReNu continued to demonstrate a favorable safety profile in the second trial, with 7.8% of ASA patients experiencing study drug-related adverse events compared to 4.0% for placebo.
• The second Phase 3 trial was a fully enrolled 594-patient, prospective, double-blind, multicenter, saline-controlled, parallel group RCT for subjects with mild to severe symptomatic knee OA.
• Statistically significant maintenance of function (p<0.0001) was observed in the second Phase 3 trial, with a WOMAC Function Scale LS Mean Difference (ASA Placebo) of -1.5.
• Organogenesis plans to request a pre-Biologics License Application (BLA) meeting with the FDA by the end of October 2025 to discuss the BLA submission pathway, potentially using combined efficacy analysis from both Phase 3 studies.
• ReNu has been studied in three large RCTs involving more than 1,300 patients combined and received FDA Regenerative Medicine Advanced Therapy (RMAT) designation in 2021 for Knee OA.

Sentiment

Score: 4

Explanation: While the second Phase 3 trial for ReNu showed numerical improvement in pain reduction and a favorable safety profile, it failed to meet its primary endpoint for statistical significance. This is a significant setback for a late-stage clinical program, increasing uncertainty regarding regulatory approval, despite the company's plan to pursue BLA submission using combined data and ReNu's RMAT designation. The mixed results lean towards a negative sentiment due to the primary endpoint miss.

Positives

• ReNu demonstrated a numerical improvement in baseline pain reduction in the second Phase 3 trial (-6.9) compared to the first trial (-6.0).
• ReNu continued to demonstrate a favorable safety profile across both trials, with a low incidence of severe or life-threatening adverse events related to the study drug.
• The second Phase 3 trial showed statistically significant maintenance of function (p<0.0001) based on the WOMAC Function Scale.
• The company plans to request a pre-BLA meeting with the FDA by the end of October 2025 to discuss submission, potentially using combined efficacy analysis from both Phase 3 studies.
• ReNu holds Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, indicating its potential to address an unmet medical need for a serious condition.
• Management expresses continued confidence in ReNu's potential as an innovative pain management product for knee OA.

Negatives

• The second Phase 3 randomized controlled trial of ReNu did not achieve statistical significance for its primary endpoint, which was the reduction in knee pain at six months.
• The p-value of 0.0393 for the primary endpoint in the second trial was above the target threshold of p=0.023, indicating a failure to meet the pre-defined statistical significance criteria.

Risks

• Risks and uncertainties inherent in clinical development.
• The FDA may require additional evidence for ReNu before a BLA can be submitted or approved, which may not be obtainable.
• Other clinical trials of ReNu may produce different results.
• Uncertainty regarding the likelihood and timing of possible regulatory approval and commercial launch of ReNu.
• Determinations by regulatory and administrative governmental authorities may delay or restrict the ability to develop or commercialize ReNu.
• Ongoing regulatory obligations and oversight impacting ReNu.
• Unforeseen safety issues resulting from the administration of ReNu in patients.
• Competing products and product candidates that may be superior to ReNu.
• Uncertainty of market acceptance and commercial success of ReNu and the impact of studies on its commercial success.
• Ability to manufacture and manage supply components for ReNu.
• Availability and extent of reimbursement of ReNu from third-party payers, including private payer healthcare and insurance programs and government programs such as Medicare and Medicaid.
• Coverage and reimbursement determinations by such payers, including local coverage determinations by Medicare Part A/B Medicare Administrative Contractors.
• New policies and procedures adopted by such payers.
• Unanticipated expenses and the costs of developing, producing, and selling ReNu.
• Ability to meet sales or other financial projections or guidance and changes to the assumptions underlying those projections or guidance.

Future Outlook

The company plans to request a pre-Biologics License Application (BLA) meeting with the FDA by the end of October 2025 to discuss the BLA submission pathway. This includes potentially using the combined efficacy analysis from both Phase 3 studies of ReNu to support an approval.

Management Comments

• "Given the first Phase 3 trial achieved a statistically significant reduction in pain compared to Saline and the second Phase 3 trial demonstrated a numerical improvement in baseline pain reduction over the first Phase 3, we believe these results support the potential approval of ReNu for pain symptoms associated with knee OA, including those patients classified as most severe." Patrick Bilbo, Chief Operating Officer.
• "As a next step, we will request a pre-BLA meeting with the FDA by the end of October to discuss the submission pathway, including using the combined efficacy analysis from both Phase 3 studies to support a BLA approval." Patrick Bilbo, Chief Operating Officer.
• "The results for ReNu support our continued confidence in the potential of ReNu as an innovative pain management product." Gary S. Gillheeney, Sr., President, Chief Executive Officer and Chair of the Board.
• "We believe ReNu, if approved, will address a significant unmet medical need for the millions of Americans suffering from symptomatic knee OA." Gary S. Gillheeney, Sr., President, Chief Executive Officer and Chair of the Board.

Industry Context

Knee Osteoarthritis (OA) is a degenerative joint disease estimated to affect over 30 million Americans, ranking among the most common causes of disability and poor quality of life. Current end-stage management often involves total knee replacement. ReNu aims to address this significant unmet medical need by offering an innovative pain management product.

Stakeholder Impact

• Shareholders: Potential negative impact due to the failure of the second Phase 3 trial to meet its primary endpoint, which could affect future revenue and stock price. However, the company's plan to pursue BLA approval using combined data offers a potential upside.
• Patients with Knee OA: If approved, ReNu could offer a new treatment option for symptomatic knee OA, addressing an unmet medical need.
• FDA: Will review the combined efficacy data from both Phase 3 studies during the pre-BLA meeting to determine the BLA submission pathway.

Next Steps

• Request a pre-Biologics License Application (BLA) meeting with the FDA by the end of October 2025.
• Discuss the BLA submission pathway with the FDA, including potentially using the combined efficacy analysis from both Phase 3 studies of ReNu to support a BLA approval.

Key Dates

Recommendation

The second Phase 3 trial for ReNu failed to achieve statistical significance for its primary endpoint, which is a critical setback for a drug candidate in late-stage development. While there were numerical improvements and a favorable safety profile, and the company plans to seek BLA approval based on combined data, the increased uncertainty surrounding FDA approval and potential delays or additional requirements significantly elevate the investment risk. This outcome suggests a more challenging and prolonged path to market, making the stock a 'sell' for risk-averse investors or those seeking clearer clinical success.

Keywords

Organogenesis, ORGO, ReNu, Knee Osteoarthritis, OA, Phase 3 Clinical Trial, Clinical Development, Biologics License Application, BLA, FDA, Regenerative Medicine, Amniotic Suspension Allograft, ASA, Pain Management, Biotechnology, Pharmaceuticals, Medical Devices